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Metals Toxicity
Certain chromium compounds are well-
established human respiratory toxins and
carcinogens for which adverse health effects
are usually associated with occupational
exposure (1). Epidemiologic studies carried
out in Europe, Japan, and the United States
have consistently shown that workers in the
chromate production industry have an ele-
vated risk of respiratory disease, perforation
of the nasal septum, development of nasal
polyps, and lung cancer (2,3). Certain
inhaled particulate chromium compounds
may persist in the lungs and cause long-term
effects. Bifurcations of the lung bronchi of
chromate workers have been found to con-
tain millimolar concentrations of chromium
more than two decades after cessation of
exposure (4). The deposition of chromium
in industrial waste, either in the form of dis-
solved chromium released to surface waters
or chromate slag used in landfills, has also
raised concerns about chromium as a poten-
tial environmental hazard (5). Investigators
have identified more than 160 chromate
production waste sites within Hudson
County, New Jersey, distributed throughout
the community in both industrial and resi-
dential areas. Frequently, the waste material
contained levels of hexavalent chromium in
the tens of parts per million (ppm) and
sometimes in excess of 100 ppm (6).
Epidemiologic, animal, and in vitro cell
studies have consistently shown that the
hexavalent form of certain particulate
chromium compounds [Cr(VI)] is the most
important toxic and carcinogenic species (1).
The main targets of Cr(VI) toxicity are lung
epithelial cells and fibroblasts exposed to
high concentrations of soluble Cr(VI) in the
immediate microenvironment of inhaled
particles (7). Soluble Cr(VI) compounds are
genotoxic (8–11) and can induce gene muta-
tions (12), sister chromatid exchanges
(8,13), and chromosomal aberrations
(14,15). In addition, Cr(VI) produces a vari-
ety of DNA lesions including DNA single-
strand breaks, DNA–protein cross-links
(DPC), Cr–DNA adducts, and ternary
DNA–Cr–DNA cross-links (Cr–DDC)
(16–25). At least one of these forms of struc-
tural DNA damage, the Cr–DDC, results in
functional damage in the form of poly-
merase-arresting lesions (26,27). Thus, solu-
ble sodium chromate (Na2CrO4) can be
used to study the genotoxic and cytotoxic
effects of Cr(VI) in cell culture.
If a cell sustains a genotoxic insult, the
damage must be repaired or bypassed before
replication to prevent death or the outgrowth
of cells with potentially oncogenic alterations.
If the damage is irreparable, the cell must be
removed from the proliferating population.
The predominant cellular fates in response to
irreparable DNA damage are terminal growth
arrest and apoptosis (28,29). Cell populations
exposed to Cr(VI) have different spectrums of
responses, depending on the extent of DNA
damage (29).
Fanconi anemia (FA) is an autosomal
recessive disorder characterized by diverse
developmental abnormalities, progressive bone
marrow failure, and a markedly increased
incidence of malignancy. FA cells are hyper-
sensitive to the DNA cross-linking agents
diepoxybutane, cisplatin, and mitomycin C,
suggesting a general defect in the repair of
DNA cross-links (30–34). Eight genetic com-
plementation groups have been described (FA-
A through FA-H), with group A accounting
for 60–65% of FA patients (30). FA-A cells
are deﬁcient in the repair of DNA interstrand
cross-links (35); thus, FA-A fibroblasts were
employed in this study. Our intent was to test
the hypothesis that human FA-A cells would
display an increased sensitivity to Cr(VI)-
induced cell death. The data suggest that the
FA-A gene (FANCA) is essential for survival
after exposure to Cr(VI).
Materials and Methods
Cell Culture
CRL cells (American Type Culture
Collection CRL-1634 cells) are normal
human foreskin fibroblasts isolated from a
newborn black male. FA-A cells (Coriell Cell
Repositories GM01309) are FA-A human
ﬁbroblasts isolated from a black male 12 years
of age. Both CRL and FA-A cells were main-
tained in minimal essential medium Eagle-
Earle media (Gibco, Grand Island, NY, USA)
supplemented with 20% fetal bovine serum
(Hyclone Laboratories, Inc., Logan, UT,
USA), 2× essential and nonessential amino
acids, vitamins, and 2 mM L-glutamine
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(Gibco). Cells were incubated in a 95% air,
5% CO2 humidiﬁed atmosphere at 37°C.
Chromium Preparation
Sodium chromate (Na2CrO4 × 4H2O) (J.T.
Baker Chemical Co., Phillipsburg, NJ, USA)
was dissolved in double-distilled water and
sterilized through a 0.2-µm ﬁlter before use.
Phosphatidylserine Translocation
The phosphatidylserine (PS) translocation
assay was used to investigate the sensitivity of
FA-A and CRL cells to Cr-induced apoptosis.
This assay measures PS translocation from
the inner (cytoplasmic) leaflet of the plasma
membrane to the outer (extracellular) leaflet
in the early stages of apoptosis. Annexin V
protein has a strong, specific affinity for PS
(36), and PS on the outer leaflet is available
for binding labeled Annexin V. Positive cells
exhibit green ﬂuorescence around the plasma
membrane. CRL and FA-A cells were seeded
at 105 cells/60-mm dish and incubated for 24
hr prior to Cr(VI) exposure. Cells were
treated with a ﬁnal concentration of 0, 1, 3,
6, or 7 µM Cr(VI) for 24 hr in complete
media. After 24 hr, the cells were rinsed twice
with 1× phosphate-buffered saline (PBS) and
incubated for an additional 24 hr in fresh
media before analysis. Cells were gently har-
vested by trypsinization, combined with non-
adherent cells from the culture medium, and
centrifuged at 600× g for 5 min. Cell pellets
were washed once in 1× PBS and resus-
pended in 100 µL binding buffer [10 mM
HEPES (pH 7.4), 150 mM NaCl, 5 mM
KCl, 1 mM MgCl2, 1.8 mM CaCl2] contain-
ing 2 µL Annexin(V)-FLUOS (Roche,
Indianapolis, IN, USA). Samples were incu-
bated in the dark at room temperature for 15
min. Thirty microliters of each sample was
loaded on a microscope slide and the percent-
age of Annexin(V)-FLUOS–stained cells was
determined by counting five fields that con-
tained at least 30 cells each on an Olympus
AX70 microscope (Olympus, Lake Success,
NY, USA) with a ﬂuorescent ﬁlter set suitable
for FLUOS analysis (excitation at 460–490
nm and emission at 515 nm).
Caspase-3 Activity
Caspase-3 is derived from the proenzyme
CPP32 at the onset of apoptosis and plays a
pivotal role in programmed cell death
(37–40). Caspase-3 exhibits the highest simi-
larity to C. elegans cell death gene of the ICE
(interleukin-1β –converting ezyme) proteases
(41). Therefore, caspase-3 is an excellent bio-
chemical indicator of apoptosis. The caspase-3
ﬂuorescent assay detects a shift in ﬂuorescence
emission of 7-amino-4-trifluoromethyl
coumarin (AFC). AFC is conjugated to a spe-
ciﬁc tetrapeptide sequence that normally emits
blue fluorescence. After the substrate is
cleaved by caspase-3, the liberated AFC emits
a yellow-green ﬂuorescence at 505 nm. Nearly
confluent 150-cm2 flasks were passaged at a
1:3 ratio and incubated for 24 hr prior to
Cr(VI) exposure. CRL and FA-A cells were
treated with a ﬁnal concentration of 0, 1, 3, 6,
or 7 µM Cr(VI) for 24 hr in complete media.
After 24 hr the cells were rinsed twice with 1×
PBS, the media was replaced, and the cells
were incubated for an additional 24 hr before
analysis. Cells were harvested by cell scraping
and combined with nonadherent cells from
the culture medium. Caspase-3 activity was
determined using the FluorAce Apopain Assay
Kit (Bio-Rad, Hercules, CA, USA) according
to manufacturer’s protocol. Cells were cen-
trifuged at 600× g for 5 min. Cell pellets were
rinsed once in 1× PBS and resuspended in
100 µL ice-cold apopain lysis buffer [10 mM
HEPES, pH 7.4, 2 mM EDTA, 0.1% 3-[(3-
cholamidopropyl)dimethylammonio]-1-
propanesulfonic acid (CHAPS), 5 mM
dithiothreitol (DTT), 1 mM phenylmethyl-
sulfonyl ﬂuoride (PMSF), supplemented with
protease inhibitors (10 µg/mL pepstatin A, 10
µg/mL aprotinin, 20 µg/mL leupeptin)
(Sigma, St. Louis, MO, USA)]. Cell suspen-
sions were vortexed gently, then freeze/thawed
4 times by transferring from an isopropanol-
dry ice bath to a 37°C water bath. Cell sus-
pensions were then centrifuged at 12,000× g
for 30 min at 4°C to pellet cell debris. Protein
concentrations of the resulting supernatants
were determined with the DC Protein Assay
II (Bio-Rad). Samples containing an equal
amount of protein were diluted to 1 mL and
transferred to wells of a CoStar 48-well dish
(Corning, Corning, NY, USA). Ten micro-
liters of apopain substrate (Ac–DEVD–AFC)
(Bio-Rad kit) and 40-µL 25× reaction buffer
(Bio-Rad kit) were added to each sample and
control. Caspase-3 enzymatically cleaves the
AFC from the peptide and releases free AFC,
which then produces a blue-green fluores-
cence. The samples were gently mixed, and
the fluorescence was determined using a
Cytofluor 4000 fluorescence multiwell plate
reader (PE Biosystems, Foster City, CA, USA)
(excitation at 320–400 nm and emission at
505–555 nm). Fluorescence readings were
taken at t = 0, t = 30, t = 60, t = 90, and t =
120 min after addition of substrate. The
amount of AFC released from the substrate
was determined by linear regression of an
AFC standard curve (per manufacturer’s
instructions) at the time point at which the
apopain positive control showed the greatest
increase. Caspase-3 activity was determined
and expressed as the ∆ AFC/min.
Clonogenicity
CRL and FA-A cells were seeded at 105
cells/100-mm dish and incubated for 24 hr
prior to Cr(VI) exposure. Cells were treated
with a ﬁnal concentration of 0, 0.01, 0.1, 0.5,
1, 2, or 3 µM Cr(VI) for 24 hr in complete
media. Cells were washed twice with 
1× PBS, collected by trypsinization, counted,
and reseeded at 2,000 cells/100-mm dish in
triplicate. The plates were incubated for 7–8
days and then rinsed with 1× PBS and incu-
bated with crystal violet stain (80% methanol,
2% formaldehyde, and 2.5 g/L crystal violet)
for 15 min at room temperature. The plates
were thoroughly rinsed with distilled water
and allowed to dry. Colonies were counted
and the means ± SE of triplicate cultures were
used to determine clonogenic survival as a per-
centage of control cultures.
Chromium Uptake
CRL and FA-A cells were seeded at 3 × 105
cells/100-mm dish and incubated for 24 hr
prior to Cr(VI) exposure. Three extra dishes
of each cell type were seeded for determining
final cell number. Cr(VI) was prepared as
above and spiked with Na2
51CrO4 (ICN,
Irvine, CA). CRL and FA-A cells were treated
with a final concentration of 0, 3, or 7 µM
Cr(VI) for 3 hr at 37°C. Following Cr(VI)
treatment, cells were harvested by trypsiniza-
tion and centrifuged at 300× g for 5 min at
4°C. Cell pellets were washed twice in 
1× PBS and lysed in 500 µL lysis buffer (10
mM Tris-Cl, 0.5% sodium dodecyl sulfate
[SDS], 0.5% Triton X-100). One hundred
microliters of each sample was combined
with Ecolite scintillation cocktail (ICN,
Irvine, CA, USA). Disintegrations per minute
(DPM) were determined on a Beckman
LS3801 scintillation counter (Beckman
Instruments, Fullerton, CA, USA). Final cell
number was determined in replicate dishes on
a Coulter cell counter (Coulter, Louton,
UK). Data were normalized to cell number.
Chromium–DNA Adducts
Cr(VI) was prepared as above and spiked with
Na2
51CrO4 (ICN). CRL and FA-A cells were
treated with 0, 3, or 7 µM Cr(VI) for 2 hr at
37°C. Following Cr(VI) treatment, cells were
harvested by trypsinization and centrifuged at
300× g for 5 min at 4°C. Cell pellets were
washed twice in 1× PBS and lysed in 500 µL
lysis buffer (10 mM Tris-Cl, 0.5% SDS, 0.5%
Triton X-100) containing 20 mg/mL pro-
teinase K overnight in a 55°C water bath.
Samples were then incubated with 10 mg/mL
RNase for 4 hr in a 37°C water bath. DNA
was extracted from the cell lysates, using phe-
nol-chloroform extraction and ethanol precip-
itation. The DNA was then quantiﬁed by its
spectrophotometric absorbance at 260 nm.
DNA-bound 51Cr was quantiﬁed by scintilla-
tion counting of an aliquot of each sample in
EcoLite scintillation cocktail (ICN). DPM
were then used to calculate Cr–DNA adducts
per 10,000 DNA base pairs.
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Statistics
Statistical significance was calculated using
the Student t-test. Significance was defined
as p < 0.05.
Results
Cr(VI) caused a dose-dependent increase in
the number of Annexin V–positive FA-A cells
(Figure 1). The percent apoptosis in the CRL
cells, as determined by PS translocation, was
12.1 and 16.4% after treatment with 6 and 7
µM Cr(VI), respectively, for 24 hr followed
by a 24-hr recovery period. This is similar to
results shown in a previous report using
human lung ﬁbroblasts (42). In comparison,
the percentage of apoptotic FA-A cells was sig-
niﬁcantly more than that of CRL cells at 43.9
and 52.4% at 6 and 7 µM doses, respectively.
To confirm the hypersensitivity of FA-A
cells to Cr(VI)-induced apoptosis using a bio-
chemical assay, we measured caspase-3 activ-
ity of extracts from Cr(VI)-treated CRL and
FA-A cells. Cr(VI) caused a dose-dependent
increase in caspase-3 activation in the FA-A
cells (Figure 2). The FA-A cells again showed
significantly more apoptosis than the CRL
cells at 6 and 7 µM Cr(VI). The caspase-3
activity/µg protein in the CRL cells was 0.06
and 0.22 units after treatment with 6 or 7
µM Cr(VI), respectively, for 24 hr, followed
by a 24-hr recovery period. In comparison,
caspase-3 activity/µg protein in the FA-A cells
was 0.75 and 1.59 units at 6 and 7 µM doses,
respectively (12- to 14-fold increase).
Clonogenicity is an indicator of long-term
cell survival and replicative potential after
exposure to a toxic agent. Cr(VI) caused a
dose-dependent decrease in clonogenic survival
in both the CRL and the FA-A cells (Figure 3).
The FA-A cells showed signiﬁcantly less clono-
genic survival after 1, 2, and 3 µM Cr(VI)
treatment compared with CRL cells. The per-
cent clonogenic survival for 1, 2, and 3 µM
Cr(VI) was 28.7, 5.4, and 0.2% for the FA-A
cells compared with 89.6, 18.6, and 4.4% for
the CRL cells, respectively.
We performed Cr(VI) uptake analysis to
determine if the differences in apoptosis and
clonogenicity could be explained by
differential Cr(VI) uptake. There was a dose-
dependent increase in Cr(VI) uptake from 0
through 7 µM Cr(VI) (Figure 4). However,
there was no signiﬁcant difference in Cr(VI)
uptake between CRL and FA-A cells at any of
the concentrations tested. Three and 7 mm
Cr(VI) resulted in approximately 8.5 × 10–4
and 1.4 × 10–3 nmol Cr per cell, respectively.
We also measured total Cr–DNA binding
in both the CRL and FA-A cells to determine
if the differences in apoptosis and clono-
genicity could be explained by differences in
Cr–DNA adduct formation. Although Cr(VI)
caused a dose-dependent increase in Cr–DNA
adduct formation in both CRL and FA-A cells
(Figure 5), there were no signiﬁcant differences
in Cr–DNA adduct formation between CRL
and FA-A cells at either the 3 or 7 µM dose.
There was a slight but not statistically signiﬁ-
cant trend toward a higher adduct level in the
CRL cells than in the FA-A cells. Three micro-
molar Cr(VI) resulted in approximately
0.02–0.03 Cr–DNA adducts per 10,000 base
pairs. Seven micromolar Cr(VI) resulted in
approximately 0.04–0.08 Cr–DNA adducts
per 10,000 base pairs. Previous studies using a
10-fold higher concentration (75 µM) Cr(VI)
resulted in approximately 2 Cr–DNA
adducts/10,000 base pairs (27).
Discussion
The carcinogenic and transformagenic
effects of Cr(VI) have been associated with
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Figure 2. Comparison of Cr(VI)-induced caspase-3
activation in CRL and FA-A cells. CRL and FA-A cells
were exposed to 0, 1, 3, 6, or 7 µM Na2CrO4 for 24 hr.
Samples were analyzed for caspase-3 activity using
the Fluorace Apopain Assay Kit (Bio-Rad). Data rep-
resent an average (± SE) of two independent experi-
ments, each done in triplicate. Asterisk (*) indicates
a statistically signiﬁcant difference (p < 0.05) relative
to vehicle control. Cross(†) indicates a statistically
signiﬁcant difference (p < 0.05) between FA-A and
CRL cells.
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Figure 3. Effect of Cr(VI) on clonogenicity. CRL and
FA-A cells exposed to 0, 0.01, 0.1, 0.5, 1, 2, or 3 µM
Na2CrO4 for 24 hr were analyzed for cloning effi-
ciency. The number of colonies for the indicated
Na2CrO4 concentrations are expressed as a per-
centage of the 0 µM control for that cell line. Data
represent an average (± SE) of three independent
experiments, each done in triplicate. Asterisk (*)
indicates a statistically significant difference (p <
0.05) relative to vehicle control. Cross (†) indicates
a statistically significant difference (p < 0.05)
between FA-A and CRL cells.
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Figure 1. Comparison of Cr(VI)-induced apoptosis in
CRL and FA-A cells. CRL and FA-A cells were
exposed to 0, 1, 3, 6, or 7 µM Na2CrO4 for 24 hr.
Samples were analyzed for percentage of apoptotic
cells by PS translocation. Data represent an aver-
age (± SE) of three independent experiments, each
done in triplicate. Asterisk (*) indicates a statistically
significant difference (p < 0.05) relative to vehicle
control. Cross (†) indicates a statistically signiﬁcant
difference (p < 0.05) between FA-A and CRL cells.
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Figure 4. Measurement of 51Cr(VI) uptake by CRL
and FA-A cells. CRL and FA-A cells were treated
with a ﬁnal concentration of 0, 3, or 7 µM Na2CrO4
spiked with Na2Cr51O4 for 3 hr at 37°C. Data repre-
sent an average (± SE) of three independent exper-
iments, each done in triplicate. Asterisk (*)
indicates a statistically significant difference (p <
0.05) relative to vehicle control.
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Figure 5. Measurement of 51Cr(VI)-DNA adducts in
CRL and FA-A cells. CRL and FA-A cells were
treated with 0, 3, or 7 µM Na2CrO4 spiked with
Na2Cr51O4 for 2 hr at 37°C. Data represent an aver-
age (± SE) of three independent experiments, each
done in duplicate. Asterisk (*) indicates a statisti-
cally significant difference (p < 0.05) relative to
vehicle control.the cytotoxicity of certain Cr(VI)-containing
compounds at the site of administration 
in vivo (1) and in cell culture systems
(12,29). In human occupational settings,
exposure to levels of particulate Cr(VI) com-
pounds usually associated with lung cancers
also effect high levels of cell death, which
manifest as nasal perforations and respira-
tory tract ulcerations (1). Several investiga-
tions have established the induction of
apoptosis by Cr(VI) in treated normal
human fibroblasts (29,42,43); thus, under-
standing the mechanisms of Cr-induced tox-
icity and cell death may help elucidate
mechanisms of carcinogenicity.
The intracellular reduction of Cr(VI)
generates several DNA-reactive species that
can lead to myriad genetic lesions. Although
a wealth of information exists concerning the
genotoxicity of Cr(VI), the specific types of
DNA damage that may be responsible for
the toxic effects of Cr(VI) have not yet been
determined. At least one type of genetic
lesion formed as a result of Cr(VI) reduction
(Cr–DDC) results in guanine-specific arrest
of DNA replication (26,27). Although
Cr–DDC may represent lethal lesions
formed by Cr(VI), information is lacking on
the effects of Cr(VI) on DNA cross-link
repair-deﬁcient cells. The focus of this inves-
tigation was to examine the cellular effects of
Cr(VI) on FA-A cells, which are specifically
deficient in the repair of DNA interstrand
cross-links (35).
The ultimate fate of a cell exposed to a
genotoxin such as Cr(VI) is heavily dependent
upon the severity of the initial insult. At low
concentrations, cells exposed to Cr(VI) pri-
marily undergo growth arrest, presumably to
allow time for repair. As the concentration of
Cr(VI) is increased, the predominate cell fate
becomes terminal growth arrest followed by
apoptosis (29). The data from the present
study are consistent with this model. The
clonogenicity assay measures the long-term
survival of a population after Cr(VI) exposure
and accounts for both growth arrest and apop-
tosis. We found that low doses of Cr(VI)
(0.1–3 µM) produced a dramatic decrease in
clonogenic survival (Figure 3). However, a
marked increase in the number of apoptotic
cells measured at a speciﬁc point in time [24 hr
after the Cr(VI) exposure] was not detected at
these doses (Figures 1, 2). These results suggest
that terminal growth arrest, not apoptotic cell
death, is the primary cell fate at this low
Cr(VI) concentration, and that FA-A cells are
more susceptible to undergo growth arrest at
these low doses compared with control cells.
At higher concentrations (6–7 µM), FA-A cells
demonstrated a statistically signiﬁcant increase
in apoptosis. These data show that FA-A cells
are markedly hypersensitive to both the
growth-inhibiting and apoptotic effects of
Cr(VI). These results are the ﬁrst to show that
FA cells are hypersensitive to an environmen-
tally relevant DNA cross-linking agent.
The hypersensitivity of FA-A cells
toward Cr(VI)-induced growth inhibition
and apoptosis was not the direct result of
higher Cr–DNA binding or Cr(VI) uptake.
There were no differences found in Cr(VI)
uptake or Cr–DNA adduct formation
between FA-A and CRL cells. It is interest-
ing however, that human FA-A fibroblasts
were markedly hypersensitive to Cr(VI)-
induced apoptosis compared with CRL cells.
These data suggest that fewer Cr–DNA
adducts (mono- and bifunctional) are
required to induce equivalent growth arrest
and apoptosis in FA-A cells relative to CRL
cells. Additionally, the similar steady-state
Cr–DNA adduct levels observed in this
study suggest that either Cr–DNA adducts
are resistant to removal in repair-competent
cells or FA-A cells do not display a defi-
ciency in Cr–DNA adduct removal.
Although the difference in Cr–DNA
adduct levels between FA-A and CRL cells
was not signiﬁcant, it is interesting that there
was a trend showing a decreased level of
Cr–DNA adducts in FA-A cells exposed to
relatively high doses of Cr(VI). This result
may be caused by the marked increase in cyto-
toxicity in FA-A cells exposed to this dose of
Cr(VI). The measurement of adduct levels
and the magnitude of statistical error may be
affected as the majority of cells progress
through apoptosis. Alternatively, perhaps the
lack of a functional DNA cross-link repair
mechanism in FA-A cells causes an altered cel-
lular response to Cr–DNA adduct formation.
It may be possible that other molecular path-
ways designed to prevent or repair the forma-
tion of DNA adducts are upregulated in FA-A
cells. Whatever the case, our results show that
FA-A cells are more susceptible to Cr(VI)-
induced growth arrest and apoptosis without
exhibiting an increase in Cr-associated DNA.
Cr(VI) produces several types of DNA
damage, and it is therefore possible that lesions
other than Cr–DDC may contribute to the dif-
ferential sensitivity of FA-A cells to chromium
toxicity. FA-A cells are speciﬁcally deﬁcient in
repair of DDC, but one must consider the pos-
sible role of chromium-induced DPC
(Cr–DPC) as well. We have shown that
Cr–DPC are preferentially formed in and
repaired from nuclear matrix DNA (44).
Others have shown that the vast majority of
Cr–DPC are actually individual amino acids or
small peptides (such as glutathione) coordi-
nated to DNA phosphate through ionic inter-
actions (45), and that this lesion is
premutagenic (46). We and others have found
that this lesion correlates strongly with altered
gene expression but not DNA replication (47).
We have recently shown that DPC are not
polymerase-arresting lesions and that their for-
mation actually precludes the formation of
polymerase-arresting lesions (48). Combining
information published by our laboratory and
others, we can identify experimental manipula-
tions that alter DPC and toxicity in an inverse
fashion (14,21,43,49). Finally, although there
is no information on FA-A cells and repair of
DPC, we think it is unlikely that the mecha-
nism of repair of this single-stranded,
non–polymerase-arresting, complex mono-
adduct would use a repair pathway designed to
remove or bypass lethal DDC, which block
progression of the replication fork.
In summary, human FA-A ﬁbroblasts were
markedly hypersensitive to Cr(VI)-induced
apoptosis compared with CRL cells, although
there were no differences found in Cr(VI)
uptake or Cr–DNA adduct formation between
FA-A and CRL cells. Because Cr(VI) produces
Cr–DDC (24–27), and FA-A cells are known
to be deficient in the repair of these lesions,
these results suggest that Cr–DDC are termi-
nal growth-arresting and/or proapoptotic
lesions. We are currently exploring the differ-
ential formation and repair of polymerase-
arresting lesions in FA-A and CRL cells.
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